---
firstreceived_date: July 29, 2015
is_fda_regulated: 'Yes'
reference: []
overall_contact_backup:
  first_name: 
  last_name: 'First line of the email MUST contain NCT# and Site #.'
  middle_name: 
  phone_ext: 
  phone: 
  degrees: 
  email: 
completion_date:
  attributes:
    type: Anticipated
  value: December 2018
responsible_party: {}
firstreceived_results_date: 
is_section_801: 'No'
detailed_description: {}
link:
- url: http://ctr.bms.com/ctd/start.do
  description: BMS Clinical Trial Information
- url: http://www.bms.com/studyconnect/Pages/home.aspx
  description: BMS clinical trial educational resource
- url: http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx
  description: Investigator Inquiry form
- url: http://www.fda.gov/MEDWATCH/safety.htm
  description: FDA Safety Alerts and Recalls
has_expanded_access: 'No'
id: NCT02515669
intervention:
- intervention_name: BMS-986089
  other_name:
  - Anti-Myostatin Adnectin
  description: 
  arm_group_label:
  - BMS-986089
  intervention_type: Biological
- intervention_name: Placebo
  other_name: []
  description: 
  arm_group_label:
  - Placebo
  intervention_type: Biological
source: Bristol-Myers Squibb
eligibility:
  gender: Male
  maximum_age: 10 Years
  sampling_method: 
  minimum_age: 5 Years
  study_pop: {}
  criteria:
    textblock: |-
      For more information regarding BMS clinical trial participation, please visit
              www.BMSStudyConnect.com

              Inclusion Criteria:

                -  Diagnosed with DMD by a blood test

                -  Able to walk without assistance

                -  Able to walk up 4 stairs in 8 seconds or less

                -  Weigh at least 15 kg

                -  Taking corticosteroids for DMD

              Exclusion Criteria:

                -  Any behavior or mental issue that will affect the ability to complete the required
                   study procedures

                -  Previously or currently taking medications like androgens, human growth hormone or
                   bisphosphonates

                -  Use of a ventilator during the day

                -  Unable to have blood samples collected or receive an injection under the skin
  healthy_volunteers: 'No'
removed_countries: {}
other_outcome: []
primary_completion_date:
  attributes:
    type: Anticipated
  value: December 2018
last_injected: '2015-10-06T22:40:24.188Z'
intervention_browse: {}
target_duration: 
number_of_arms: '2'
start_date: November 2015
why_stopped: 
id_info:
  org_study_id: CN001-006
  secondary_id: []
  nct_alias: []
  nct_id: NCT02515669
acronym: 
arm_group:
- description: BMS-986089 subcutaneous injections on specified days
  arm_group_label: BMS-986089
  arm_group_type: Active Comparator
- description: Placebo subcutaneous injections on specified days
  arm_group_label: Placebo
  arm_group_type: Placebo Comparator
sponsors:
  collaborator: []
  lead_sponsor:
    agency: Bristol-Myers Squibb
    agency_class: Industry
secondary_outcome:
- safety_issue: 'No'
  time_frame: Day 8 through Week 24
  description: 
  measure: Trough concentrations of BMS-986089
- safety_issue: 'No'
  time_frame: Day 1 and 29
  description: 
  measure: Maximum observed concentration (Cmax) of BMS-986089
- safety_issue: 'No'
  time_frame: Day 8 through Week 24
  description: 
  measure: Frequency of subjects with positive anti-BMS-986089 antibodies (ADA) assessment
- safety_issue: 'No'
  time_frame: Day 8 through Week 24
  description: 
  measure: Frequency of subjects who develop positive ADA following a negative baseline
- safety_issue: 'No'
  time_frame: Day 8 through Week 24
  description: 
  measure: Anti-BMS-986089 antibodies on selected days
- safety_issue: 'No'
  time_frame: Day 8 through Week 24
  description: 
  measure: Serum concentration of free myostatin
- safety_issue: 'No'
  time_frame: Day 8 through Week 24
  description: 
  measure: Change from baseline in volume of thigh muscle contractile and non-contractile
    tissue
- safety_issue: 'No'
  time_frame: Day 8 through Week 24
  description: 
  measure: Change from baseline in thigh muscle lipid fraction
- safety_issue: 'No'
  time_frame: Day 8 through Week 24
  description: 
  measure: Change from baseline in thigh muscle maximal cross sectional area
- safety_issue: 'No'
  time_frame: Day 8 through Week 24
  description: 
  measure: Serum concentration of drug-myostatin complex
- safety_issue: 'No'
  time_frame: Day 8 through Week 24
  description: 
  measure: Serum concentration of percent inhibition of free myostatin at trough
study_type: Interventional
biospec_retention: 
overall_status: Not yet recruiting
primary_outcome:
- safety_issue: 'Yes'
  time_frame: 24 weeks
  description: Adverse event (AEs)
  measure: Safety and Tolerability based on number of incidences of AEs, serious AEs,
    AEs leading to discontinuation and death, as well as marked treatment emergent
    abnormalities in clinical laboratory tests
- safety_issue: 'Yes'
  time_frame: 24 weeks
  description: 
  measure: Safety and Tolerability based on number of incidences of vital sign measurements,
    ECGs, echocardiograms, and physical examinations
overall_official:
- first_name: 
  last_name: Bristol Myers Squibb
  middle_name: 
  affiliation: Bristol-Myers Squibb
  degrees: 
  role: Study Director
phase: Phase 1/Phase 2
location_countries:
  country:
  - United States
condition:
- Muscular Dystrophy (DMD)
clinical_results: {}
study_design: 'Allocation: Randomized, Endpoint Classification: Safety Study, Intervention
  Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator,
  Outcomes Assessor), Primary Purpose: Basic Science'
keyword: []
results_reference: []
oversight_info:
  has_dmc: 'Yes'
  authority:
  - 'United States: Institutional Review Board'
  - 'United States: Food and Drug Administration'
number_of_groups: 
location:
- status: Not yet recruiting
  contact_backup: {}
  facility:
    name: Local Institution
    address:
      city: Los Angeles
      state: California
      zip: '90095'
      country: United States
  investigator: []
  contact:
    first_name: 
    last_name: Site 0008
    middle_name: 
    phone_ext: 
    phone: 
    degrees: 
    email: 
  geodata:
    latitude: 34.052
    formatted: Los Angeles, CA, USA
    longitude: -118.244
    original: Los Angeles, California
- status: Not yet recruiting
  contact_backup: {}
  facility:
    name: Local Institution
    address:
      city: Palo Alto
      state: California
      zip: '94304'
      country: United States
  investigator: []
  contact:
    first_name: 
    last_name: Site 0004
    middle_name: 
    phone_ext: 
    phone: 
    degrees: 
    email: 
  geodata:
    latitude: 37.442
    formatted: Palo Alto, CA, USA
    longitude: -122.143
    original: Palo Alto, California
- status: Not yet recruiting
  contact_backup: {}
  facility:
    name: Local Institution
    address:
      city: Sacramento
      state: California
      zip: '95817'
      country: United States
  investigator: []
  contact:
    first_name: 
    last_name: Site 0007
    middle_name: 
    phone_ext: 
    phone: 
    degrees: 
    email: 
  geodata:
    latitude: 38.582
    formatted: Sacramento, CA, USA
    longitude: -121.494
    original: Sacramento, California
- status: Not yet recruiting
  contact_backup: {}
  facility:
    name: Local Institution
    address:
      city: Gainesville
      state: Florida
      zip: '32611'
      country: United States
  investigator: []
  contact:
    first_name: 
    last_name: Site 0002
    middle_name: 
    phone_ext: 
    phone: 
    degrees: 
    email: 
  geodata:
    latitude: 29.652
    formatted: Gainesville, FL, USA
    longitude: -82.325
    original: Gainesville, Florida
- status: Not yet recruiting
  contact_backup: {}
  facility:
    name: Local Institution
    address:
      city: Orlando
      state: Florida
      zip: '32827'
      country: United States
  investigator: []
  contact:
    first_name: 
    last_name: Site 0005
    middle_name: 
    phone_ext: 
    phone: 
    degrees: 
    email: 
  geodata:
    latitude: 28.538
    formatted: Orlando, FL, USA
    longitude: -81.379
    original: Orlando, Florida
- status: Not yet recruiting
  contact_backup: {}
  facility:
    name: Local Institution
    address:
      city: Atlanta
      state: Georgia
      zip: '30342'
      country: United States
  investigator: []
  contact:
    first_name: 
    last_name: Site 0012
    middle_name: 
    phone_ext: 
    phone: 
    degrees: 
    email: 
  geodata:
    latitude: 33.749
    formatted: Atlanta, GA, USA
    longitude: -84.388
    original: Atlanta, Georgia
- status: Not yet recruiting
  contact_backup: {}
  facility:
    name: Local Institution
    address:
      city: Chicago
      state: Illinois
      zip: '60612'
      country: United States
  investigator: []
  contact:
    first_name: 
    last_name: Site 0006
    middle_name: 
    phone_ext: 
    phone: 
    degrees: 
    email: 
  geodata:
    latitude: 41.878
    formatted: Chicago, IL, USA
    longitude: -87.63
    original: Chicago, Illinois
- status: Not yet recruiting
  contact_backup: {}
  facility:
    name: Local Institution
    address:
      city: Kansas City
      state: Kansas
      zip: '66160'
      country: United States
  investigator: []
  contact:
    first_name: 
    last_name: Site 0011
    middle_name: 
    phone_ext: 
    phone: 
    degrees: 
    email: 
  geodata:
    latitude: 39.114
    formatted: Kansas City, KS, USA
    longitude: -94.627
    original: Kansas City, Kansas
- status: Not yet recruiting
  contact_backup: {}
  facility:
    name: Local Institution
    address:
      city: Baltimore
      state: Maryland
      zip: '21205'
      country: United States
  investigator: []
  contact:
    first_name: 
    last_name: Site 0009
    middle_name: 
    phone_ext: 
    phone: 
    degrees: 
    email: 
  geodata:
    latitude: 39.29
    formatted: Baltimore, MD, USA
    longitude: -76.612
    original: Baltimore, Maryland
- status: Not yet recruiting
  contact_backup: {}
  facility:
    name: Local Institution
    address:
      city: St. Louis
      state: Missouri
      zip: '63110'
      country: United States
  investigator: []
  contact:
    first_name: 
    last_name: Site 0003
    middle_name: 
    phone_ext: 
    phone: 
    degrees: 
    email: 
  geodata:
    latitude: 38.627
    formatted: St Louis, MO, USA
    longitude: -90.199
    original: St. Louis, Missouri
- status: Not yet recruiting
  contact_backup: {}
  facility:
    name: Local Institution
    address:
      city: Cincinnati
      state: Ohio
      zip: '45229'
      country: United States
  investigator: []
  contact:
    first_name: 
    last_name: Site 0010
    middle_name: 
    phone_ext: 
    phone: 
    degrees: 
    email: 
  geodata:
    latitude: 39.103
    formatted: Cincinnati, OH, USA
    longitude: -84.512
    original: Cincinnati, Ohio
- status: Not yet recruiting
  contact_backup: {}
  facility:
    name: Local Institution
    address:
      city: Pittsburgh
      state: Pennsylvania
      zip: '15224'
      country: United States
  investigator: []
  contact:
    first_name: 
    last_name: Site 0001
    middle_name: 
    phone_ext: 
    phone: 
    degrees: 
    email: 
  geodata:
    latitude: 40.441
    formatted: Pittsburgh, PA, USA
    longitude: -79.996
    original: Pittsburgh, Pennsylvania
official_title: A Multi-site, Randomized, Placebo-controlled, Double-blind, Multiple
  Ascending Subcutaneous Dose Study to Evaluate the Safety Tolerability and Pharmacokinetics
  of BMS-986089 in Ambulatory Boys With Duchenne Muscular Dystrophy
verification_date: August 2015
required_header:
  url: https://clinicaltrials.gov/show/NCT02515669
  link_text: Link to the current ClinicalTrials.gov record.
overall_contact:
  first_name: 
  last_name: 'Recruiting sites have contact information. Please contact the sites
    directly. If there is no contact information, please email:'
  middle_name: 
  phone_ext: 
  phone: 
  degrees: 
  email: Clinical.Trials@bms.com
brief_title: Study of BMS-986089 in Ambulatory Boys With DMD
biospec_descr: {}
condition_browse:
  mesh_term:
  - Muscular Dystrophies
brief_summary:
  textblock: |-
    The purpose of this study is to determine the safety and tolerability of BMS-986089 in boys
          with Duchenne Muscular Dystrophy.
enrollment:
  attributes:
    type: Anticipated
  value: '40'
lastchanged_date: October 5, 2015
